CatalYm

CatalYm is a preclinical biotech company developing therapies to address cancer resistance.

On the heels of early-stage data for cancer drug visugromab showing “impressive and lasting responses," CatalYm has secured a $150 million series D.

Darren Incorvaia Jul 16, 2024 5:00am